Pulmonary Oncocytic Carcinoid: 1 Case report / 대한흉부외과학회지

Oncocytic carcinoid is a very rare tumor and only few cases have been reported in the literatures. We have experienced one case of pulmonary oncocytic carcinoid occuring at the left upper lobe. The patient was a 56 years old female with no spedific symptoms. Chest Computed tomography showed about 3X3.5cm sized homogenous mass at the left upper lobe. After the evaluation, surgical resection was performed. Gross finding showed a well-defined and well-encapsulated mass of 3X4cm in size, and yellowish-gray in color. Pathohistologically, the tumor was abundant granular eosinophilic cytoplasm. Immunohistochemical stain showed positive cytokeratin and was focal positive reaction in EMA and chromograin. It was confirmed as pulmonary oncocytic carcinoid. Postoperative course was uneventful and the patient has been followed up with no problem.

Serum Epeidermal Growth Factor Receptor (EGFR) in Cervical Cancer / 대한부인종양콜포스코피학회잡지

Epidermal growth factor receptor (EGFR) is overexpressed in various malignancies including carcinoma of the breast, lung, esophagus, cervix, and stomach. In patients with cervical carcinoma, its overexpression may be associated with advanced stage and poor prognosis. So, we evaluated the levels of serum EGFR in patients with cervical carcinoma. The level of EGFR extracellular domain was determined in serum from 57 cervical carcinoma patients(adenocarcinoma: 2, squamous cell carcinoma: 39, carcinoma in situ(CIS): 16) and 28 cases of healthy control using enzyme-linked immunosorbent assay(Calbiochem). In invasive carcinoma, serum EGFR level was measured in 11 cases of Stage Ia, 9 cases of Stage Ib, 4 cases of Stage IIa, 15 cases of Stage IIb, 2 cases of stage III patients. The mean ages of the healthy controls, of the wome with carcinoma in situ(CIS), and with invasive cervical carcinoma were not different(49.3, 44,4, 49.5, respectively, p 0.241). The mean serum level of EGFR in healthy control(n 28), carcinoma in situ(CIS)(n 16), and invasive carcinoma patients(n=41) were not significantly different(71.4+/-12.8fmol/ml, 79.2+/-26.8fmol/ml, 61.8+/- 18.4 fmol/ml, respectively, p=0.071). In conclusion, the expression of EGFR was not increased in patients with cervical cancer compared with normal women. And no significant differences were found depending on the clinical stage.